Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer.

HER2 detection is important for breast cancer (BC) treatment and prognosis, but the detection methods currently used have some disadvantages. Quantum dots (QDs)-based probes provide a potentially important new method for HER2 detection in clinical practice. This potential is examined in this paper. A QDs HER2 probe kit and QDs image acquisition and analysis software were developed and applied to 94 clinical samples of BC. Compared to conventional immunohistochemistry techniques, this method provided a superior accurate and sensitive method for the detection of HER2 in clinical breast cancer diagnosis.

[1]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[2]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[3]  Wei-xing Zhu,et al.  [Analysis of the incidence and survival of female breast cancer in Beijing during the last 20 years]. , 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[4]  D. Pang,et al.  The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. , 2008, Biomaterials.

[5]  Shuming Nie,et al.  Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry , 2007, Nature Protocols.

[6]  Sudhir Srivastava,et al.  Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection , 2008, International journal of cancer.

[7]  C. de Wolf‐Peeters,et al.  The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity , 2007, Current opinion in oncology.

[8]  M. Dowsett,et al.  Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.

[9]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[10]  L. Goldstein,et al.  HER-2 testing in breast cancer using parallel tissue-based methods. , 2004, JAMA.

[11]  L. Huo.  HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .

[12]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[13]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[14]  E. Tholouli,et al.  Quantum dots light up pathology , 2008, The Journal of pathology.

[15]  C. Wells,et al.  Predictive markers in breast cancer – the present , 2007, Histopathology.

[16]  R. Nitschke,et al.  Quantum dots versus organic dyes as fluorescent labels , 2008, Nature Methods.

[17]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  H. Tsuda.  HER-2 (c-erbB-2) test update: Present status and problems , 2006, Breast cancer.

[19]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Kim,et al.  The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer , 2007, Journal of Clinical Pathology.

[21]  Noriaki Ohuchi,et al.  In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. , 2007, Cancer research.

[22]  D. Pang,et al.  Fluorescence Analysis with Quantum Dot Probes for Hepatoma Under One- and Two-Photon Excitation , 2007, Journal of Fluorescence.

[23]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[24]  D. Birnbaum,et al.  Comparative multi‐methodological measurement of ERBB2 status in breast cancer , 2004, The Journal of pathology.

[25]  L. True,et al.  Quantum dots for molecular pathology: their time has arrived. , 2007, The Journal of molecular diagnostics : JMD.

[26]  Shuming Nie,et al.  In Situ Molecular Profiling of Breast Cancer Biomarkers with Multicolor Quantum Dots , 2007 .

[27]  Libo Zeng,et al.  A method based on multispectral imaging technique for White Blood Cell segmentation , 2007, Comput. Biol. Medicine.

[28]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[29]  Ron C. Hardman.  A Toxicologic Review of Quantum Dots: Toxicity Depends on Physicochemical and Environmental Factors , 2005, Environmental health perspectives.

[30]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[31]  Yi Ding,et al.  Study of rice pollen grains by multispectral imaging microscopy , 2005, Microscopy research and technique.

[32]  D. Parkin,et al.  [Time trends, estimates and projects for breast cancer incidence and mortality in China]. , 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[33]  G. Barosi,et al.  Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[35]  R M Levenson,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.

[36]  Yan Li,et al.  Advances in the application of quantum dots in tumor markers investigation , 2008 .

[37]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[38]  M E Dickinson,et al.  Multi-spectral imaging and linear unmixing add a whole new dimension to laser scanning fluorescence microscopy. , 2001, BioTechniques.